Aktive Positionen von Thomas Blankenstein
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Direktor/Vorstandsmitglied | 01.01.2018 | - |
| Gründer | 01.01.2018 | - |
Karriereverlauf von Thomas Blankenstein
Ehemalige bekannte Positionen von Thomas Blankenstein
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Medigene Immunotherapies GmbH
 Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Gründer | 02.01.2013 | - |
Statistik
International
| Deutschland | 3 |
Operativ
| Founder | 2 |
| Director/Board Member | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
- Börse
- Insiders
- Thomas Blankenstein
- Erfahrung
